For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SKH865. CME/MOC/AAPA/IPCE credit will be available until March 20, 2025.
Making Precision Decisions in the Treatment of NSCLC With Common and Uncommon EGFR Mutations: How to Navigate the Expanding Options and Increasing Complexity
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by independent educational grants from AstraZeneca and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Disclosure Policy
All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Faculty/Planner Disclosures
Chair/Planner
Joshua Sabari, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; Navire; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi Genzyme; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Boehringer Ingelheim Pharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Mirati Therapeutics, Inc.; and Regeneron Pharmaceuticals Inc.
Faculty/Planner
Jyoti D. Patel, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; AnHeart Therapeutics; AstraZeneca; Blueprint Medicines Corporation; Daiichi Sankyo, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Sanofi; and Takeda Pharmaceutical Company Limited.
Other Financial or Material Support for Travel from Daiichi Sankyo, Inc. and Tempus.
Faculty/Planner
Alexander I. Spira, MD, PhD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Array BioPharma Inc.; AstraZeneca/ MedImmune; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc./AstraZeneca; Incyte; Gritstone bio, Inc.; Janssen Research & Development; Jazz Pharmaceuticals, Inc.; Lily; Merck & Co., Inc.; Mersana Therapeutics; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from ADC Therapeutics SA; AbbVie Inc.; Alkermes; Amgen Inc.; Arch Therapeutics, Inc.; ArriVent Biopharma; Astellas Pharma US, Inc.; Astex Pharmaceuticals; AstraZeneca; Black Diamond Therapeutics; Blueprint Medicines Corporation; Bluprint Oncology; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; Gritstone bio, Inc.; Ignyta Inc; Incyte; Janssen Oncology; LAM Therapeutics, Inc.; Loxo Oncology; MacroGenics, Inc.; Medikine, Inc; MedImmune; Mersana Therapeutics; Mirati Therapeutics, Inc.; NALO Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Plexxikon; Regeneron Pharmaceuticals Inc.; Revolution Medicines, Inc.; Rubius Therapeutics; Scorpion Therapeutics; Synthekine; and Takeda Pharmaceutical Company Limited.
Honoraria from Amgen Inc.; AstraZeneca/ MedImmune; Bayer; Bristol Myers Sqiubb; CytomX Therapeutics, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; and Takeda Pharmaceutical Company Limited.
Stock Shareholder in Lilly.
Planning Committee and Reviewer Disclosures
Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smarter Approaches for Diagnosing HoFH
Seth S. Martin, MD, MHS, FACC, FAHA, FASPC - Medicine in Motion: Smart Approaches for Treating HoFH
Nasser Altorki, MD, Jonathan D. Spicer, MD, PhD, FRCSC - Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Mult
Jessica Donington, MD, Catherine Shu, MD - EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know
Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP - Improving Outcomes for Hospitalized Patients with COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice
Nathan A. Pennell, MD, PhD, FASCO - Fine-Tuning Biomarker Testing to Identify and Target RET Fusions as Uncommon But Actionable Genomic Alterations in NSCLC
Nikhil C. Munshi, MD - The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes
Grzegorz (Greg) Nowakowski, MD - Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care
Guillermo Garcia-Manero, MD - The Future is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management
Jay B. Wish, MD - Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?
Javid Moslehi, MD - Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Re
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 8: VTE in Cancer: How Concerning Is It and What Do We Do About It?
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 7: How Should VTE Be Managed in Patients With Obesity?
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 6: What Is Real-World Evidence and How Is It Relevant and Important in VTE?
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 5: Knocking Down Barriers in Transitions of Care
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 4: How Can We Talk About VTE to Our Patients?
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 2: Tools for Unmasking VTE Quickly
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 3: Anticoagulation: When to Use It, With What, and for How Long?
Javed Butler, MD, MPH, MBA - How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure
Drs. Alexander (Ander) T. Cohen / Steven B. Deitelzweig - Episode 1: Why Are We Talking About VTE?
Create your
podcast in
minutes
It is Free
PeerView Neuroscience & Psychiatry CME/CNE/CPE Audio Podcast
PeerView Internal Medicine CME/CNE/CPE Audio Podcast
PeerView Endocrinology & Diabetes CME/CNE/CPE Audio Podcast
PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast
PeerView Gastroenterology CME/CNE/CPE Audio Podcast